x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Ace Therapeutics is experienced in the development, identification, and validation of diabetes-related biomarkers. Our glucose-related biomarker development services, which leverage multiple technologies, strong project management, and expertise, provide accurate, reliable information to help clients advance in diabetes diagnosis and therapy development. Our dedicated teams, platforms, and instrumentation enable biotechnology and pharmaceutical companies to make informed decisions and accelerate drug development through comprehensive analysis of target biomarkers and custom assay development.
Biomarkers enable effective diagnosis of diabetes before it develops into overt diabetes, facilitate mechanistic studies, and provide surrogate endpoints for evaluating preventive and therapeutic interventions. Glucose-related biomarker typically include:
| Glucose-Related Biomarker | Characteristics | Applications |
|---|---|---|
| Fasting blood glucose | Diabetes screening and diagnosis |
|
| Hemoglobin A1c | An important indicator of long-term glycaemic control |
|
| Glycated albumin | Reflect the average blood glucose level over the past 2-3 weeks and is suitable for short-term blood glucose monitoring. |
|
| Fructosamine (FA) | Indicators of short-term glycaemic control. |
|
| 1,5-Anhydroglucitol (1,5-AG) | 1,5-AG levels correlate with blood glucose fluctuations, and low levels usually indicate recent hyperglycaemia. |
|
Ace Therapeutics offers a one-stop shop for glycaemic biomarker discovery services, including high-throughput sequencing, functional genomics analysis services, database mining services, bioinformatic analysis and more. By identifying candidate glucose-related biomarkers at an early stage, we can reduce the risk of antidiabetic drug development and optimize trial design using our biomarker discovery services.
We centrally validate the performance of initially screened biomarkers with independent samples to assess their diagnostic accuracy, sensitivity and specificity. Our experienced team of experts selects the appropriate validation technique and conducts a thorough technical evaluation to meet the needs of the later stage of the experiment.
Ace Therapeutics has a variety of technology platforms available for the detection and development of diabetes-related glycaemic biomarkers. Whether it is early discovery or large-scale validation of glucose-related biomarkers, Ace Therapeutics can provide the right technology and services to meet our customers' R&D needs.
Ace Therapeutics is committed to providing comprehensive glucose-related biomarker development services. Please contact us to discuss your specific project needs and we will be happy to assist you.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
